Related Experiment Video
Updated: Dec 31, 2025
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
10.0K
[Myelodysplastic syndromes]
1Klinik für Onkologie, Hämatologie und Palliativmedizin, Marien Hospital Düsseldorf, Rochusstr. 2, 40479, Düsseldorf, Deutschland. aristoteles.giagounidis@vkkd-kliniken.de.
Der Internist
|January 12, 2020
Summary
Myelodysplastic syndromes (MDS) are clonal stem cell diseases causing low blood counts and potential acute myeloid leukemia transformation. Risk stratification impacts survival, with genetic mutations driving disease progression.
Area of Science:
- Hematology
- Oncology
- Stem Cell Biology
Background:
- Myelodysplastic syndromes (MDS), previously termed "preleukemias," are clonal disorders originating from pluripotent hematopoietic stem cells.
- Characterized by peripheral cytopenias, MDS involves cellular dysplasia in bone marrow and can progress to acute myeloid leukemia in approximately 30% of cases.
Purpose of the Study:
- To summarize the key features, prognostic factors, and therapeutic landscape of Myelodysplastic Syndromes.
- To highlight the genetic underpinnings and clinical heterogeneity of MDS.
Main Methods:
- Review of existing literature on Myelodysplastic Syndromes.
- Analysis of clinical characteristics, genetic mutations, and treatment modalities.
Main Results:
- MDS affects the elderly, with prognoses ranging from 6 months to 10 years based on risk stratification.
- Chromosomal abnormalities are found in 50% of patients, and gene mutations in 80%, driving differentiation defects and blast accumulation.
- Therapeutic strategies encompass supportive care, erythropoiesis-stimulating agents, demethylating agents, and allogeneic stem cell transplantation.
Conclusions:
- MDS is a heterogeneous group of stem cell disorders with significant transformation potential to acute myeloid leukemia.
- Genetic abnormalities play a crucial role in MDS pathogenesis, influencing disease progression and patient outcomes.
- Treatment decisions for MDS are guided by risk stratification and involve a spectrum of interventions from supportive care to stem cell transplantation.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
01:25Cardiomyopathy I: Introduction and Classification
431
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
431
02:18Alternative RNA Splicing
24.5K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
24.5K
01:27Disorders of Erythrocytes
2.0K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.0K
02:23Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
01:15Differentiation of Common Myeloid Progenitor Cells
3.8K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.8K